Paper Search Console

Home Search Page About Contact

Journal Title

Title of Journal: PharmacoEconomics

Search In Journal Title:

Abbravation: PharmacoEconomics

Search In Journal Abbravation:

Publisher

Springer International Publishing

Search In Publisher:

DOI

10.1007/s10569-013-9485-8

Search In DOI:

ISSN

1179-2027

Search In ISSN:
Search In Title Of Papers:

Big Data and Its Role in Health Economics and Outc

Authors: Eberechukwu Onukwugha
Publish Date: 2016/01/25
Volume: 34, Issue: 2, Pages: 91-93
PDF Link

Abstract

Health economists and outcomes researchers have watched the term ‘big data’ increase in prominence over the last several years However to date the use of big data in medicine has not been concretely illustrated across a variety of health economics and outcomes research HEOR At the same time many of the same observers agree that fundamental questions remain unanswered and include 1 “What does the term ‘big data’ mean” and 2 “What does the availability of big data mean for individuals who produce and use findings from HEOR” This editorial tackles the first question and leaves contributors to this issue of PharmacoEconomics to discuss the promises possibilities and potential pitfalls of using big data in HEORBig data refers to large amounts of information that require new technologies for capture storage or analysis due in part to the amount of information the speed at which it is generated and its content Two approaches have been used in formally defining big data 1 the 3V definition 2 3 and the 4V definition 4 The 3V definition includes volume variety and velocity 2 3 According to Berman 2 for data to be properly characterized as big data we must be able to talk about “the size complexity and restlessness” of the data The 4V definition adds ‘value’ to the list 4 In their description of big data Gantz and Reinsel 4 note that big data “is not only about the original content stored or being consumed but also about the information around its consumption” Thus big data involves technology and system architecture not only content Smartphones are often used to illustrate the complexity of big data In addition to providing information that is easily captured as flat files or simpleformat records they can also provide more complex data like geographic location motion and direction information 2In this section the 4V definition is used to describe big data in terms of its volume variety velocity and value The large amounts of information from health records social media server logs Web clickstream machine/sensor and geolocation data illustrate the volume of big data 2 5 The variety of big data represents the different potential sources eg administrative data electronic health records sensors smartphones social networks and formats eg video audio text or image 1 2 The velocity of big data relates to the speed at which data transfers occur as well as to the rapidly changing nature of the data due to the sources formats and categories of the contributing data 1 2 Value “the most important aspect of big data” 1 relates to the untapped potential for drawing important unique and transformative insights from big data This fourth characteristic of big data has important implications for clinical research and population health research 6 This special issue focuses on the application to population health research and particularly HEORThe fulllength articles in this special issue draw on one or more of the components of the 4V definition and contribute to our understanding of the role of big data in HEOR Contributions were sought that addressed important aspects of HEOR including data sources measurement regression modelling and simulation Additionally the goal was to include a geographically diverse set of applications to highlight perspectives across institutional government and health system settings The articles illustrate innovative linked data sources and discuss practical considerations for their development reliability and use in HEOR eg Lorgelly et al 7 and Thorn et al 8 The articles discuss the practical challenges and opportunities with regards to measurement of healthcare cost and utilization using large complex datasets eg Canavan et al 9 Payakachat et al 10 Asaria et al 11 The articles utilize analytic methods and tools that are particularly suited for developing evidence from largevolume datasets These articles illustrate the use of classification and regression trees for analysing prescribing patterns 12 clustering algorithms for cost prediction 13 and data visualization tools for examining prescription drug fill patterns 14 Last but not least the fulllength articles in this special issue describe innovative opportunities for linking dynamic simulation modelling DSM with electronic health records 15 and integrating DSM with big data for evidence generation 16Together these articles offer a muchneeded snapshot of current data sources analytic methods opportunities and challenges The hope is that future work will offer additional insights and lessons learned to increase our knowledge of the role of big data in HEOR This knowledge base is important given that observational data whether used for regression or simulation modelling are critical to evidence generation in HEOR We will need to be sure that big data provide more value and not more noise As we consider the availability of more complex data we cannot forget what we already know about the importance of study design or the appropriate interpretation of study findings We cannot assume that more data necessarily means more information Indeed as the volume of data increases it will be important to pay continued or more attention to established concerns regarding measurement bias and fallacies relevant to empirical analysis and interpretation We should keep in mind points offered in William Crown’s commentary 17 on model specification and big data including his point that more data is not an automatic source of bias reduction It is also important to note the strengths weaknesses opportunities and threats discussed in Brendan Collins’ commentary 18With regards to the role of big data in HEOR we will need thoughtful data linkages model specifications and interpretation to leverage the potential of big data We will also need richer measures including environmental measures eg physical and social environmental measures of place and space economic measures eg income measured at an individual or smallarea level clinical measures ‘health record’type detail with ‘experimental study’type accuracy and utilization measures including accurate validated measures where needed In addition we should have a clear sense of what may be missing eg preferences opportunity costs direct nonmedical and intangible costs and who may be missing eg the uninsured the homeless the medically underserved the insured individual who does not utilize health services from the data to identify creative ways to leverage the breadth and depth of big dataThe papers in this special issue provide practical provocative discussions regarding the use of large complex data in HEOR We hope that these papers spur continued discussions because the availability of big data is neither a silver bullet nor a temporary distraction Developments in information technology will support its continued relevance into the foreseeable future The opportunities for linking clinical cost and contextual data as well as the challenges that arise in this undertaking are welcome developments They challenge us to continue efforts to improve the conduct and translation of HEOR for realworld impactOpen AccessThis article is distributed under the terms of the Creative Commons AttributionNonCommercial 40 International License http//creativecommonsorg/licenses/bync/40/ which permits any noncommercial use distribution and reproduction in any medium provided you give appropriate credit to the original authors and the source provide a link to the Creative Commons license and indicate if changes were made


Keywords:

References


.
Search In Abstract Of Papers:
Other Papers In This Journal:

  1. Análisis farmacoeconómico del tratamiento de la deficiencia de hierro con hierro carboximaltosa (Ferinject®) en España
  2. For a Step Change to Curb the Obesity Epidemic
  3. ESSENCE
  4. Coste-efectividad de dalteparina en la profilaxis y manejo de la enfermedad tromboembólica venosa (ETV) asociada al paciente adulto médico y quirúrgico en México
  5. Risperidone more cost effective than olanzapine in schizophrenia?
  6. Review of Models Used in Economic Analyses of New Oral Treatments for Type 2 Diabetes Mellitus
  7. ‘Viagra’ making headlines again in the UK
  8. Reform der Erstattungs- und Preisregulierung von verschreibungspflichtigen Arzneimitteln auf dem Markt der gesetzlichen Krankenversicherungen in Deutschland
  9. Calculating Total Health Service Utilisation and Costs from Routinely Collected Electronic Health Records Using the Example of Patients with Irritable Bowel Syndrome Before and After Their First Gastroenterology Appointment
  10. Trastuzumab for the Treatment of HER2-Positive Metastatic Gastric Cancer
  11. Cost Implications of Value-Based Pricing for Companion Diagnostic Tests in Precision Medicine
  12. I costi del dolore cronico/ricorrente in medicina generale
  13. The Problem of Embedded Decision Nodes in Cost-Effectiveness Decision Trees
  14. Análisis farmacoeconómico del tratamiento de las infecciones complicadas de piel y tejidos blandos con tigeciclina o la combinación de vancomicina y aztreonam en España
  15. Resource Modelling: The Missing Piece of the HTA Jigsaw?
  16. Impacts of Health Insurance Benefit Design on Percutaneous Coronary Intervention Use and Inpatient Costs among Patients with Acute Myocardial Infarction in Shanghai, China
  17. “Lost in Translation”
  18. Cost-Effectiveness Analysis of Pharmaceutical Treatment Options in the First-Line Management of Major Depressive Disorder in Belgium
  19. Moving from demand management to disease management
  20. Impiego di un’associazione fissa di formoterolo e budesonide nel trattamento del paziente asmatico

Search Result: